Clinical trial · Interventional
Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
Correlative Study of Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This correlative study aims to understand the pharmacodynamic effects and clonal dynamics in response to epcoritamab by obtaining and analyzing lymph node, bone marrow, and blood samples from subjects enrolled in GCT3013-03 trial sponsored by Genmab at NIH. Samples will be collected before and at multiple time points during treatment with epcoritamab. National Heart, Lung, and Blood Institute (NHLBI) investigators are experienced in testing samples treated with bsAb2,3 including epcoritamab in an ongoing pre-clinical collaboration with Genmab. Addressing the objectives of this correlative study will advance the science and clinical application of epcoritamab specifically as well as T-cell engaging bsAb in general as an emerging class of immunotherapy for cancer. The study is enrolling by invitation only.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Chronic Lymphocytic | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Richter Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| epcoritamab | Drug | Epcoritamab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- epcoritamab
- description
- Samples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
- interventionNames
- Drug: epcoritamab
Primary outcomes (1)
- measure
- Immunophenotype and transcriptome of T cells and tumor cells in lymph node and bone marrow
- timeFrame
- 25 days (Cycle 1 Day 25)
Secondary outcomes (2)
- measure
- Immunophenotype and transcriptome of T cells and tumor cells in peripheral blood
- timeFrame
- 167 Days (Cycle 7 Day 1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Must be undergoing screening for GCT3013-03 * Stated willingness to comply with all study procedures and availability for the duration of the study * Ability of subject to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: None
References
Publications (0)
Data not yet available